Last updated: 15 June 2019 at 2:03am EST

Arch Management Iv, L.L.C.J... Net Worth




The estimated Net Worth of Arch Management Iv, L.L.C.J... is at least $3.18 Million dollars as of 18 November 2014. Arch J owns over 250,000 units of Concert Pharmaceuticals Inc stock worth over $102,959 and over the last 10 years Arch sold CNCE stock worth over $3,072,500.

Arch J CNCE stock SEC Form 4 insiders trading

Arch has made over 1 trades of the Concert Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Arch sold 250,000 units of CNCE stock worth $3,072,500 on 18 November 2014.

The largest trade Arch's ever made was selling 250,000 units of Concert Pharmaceuticals Inc stock on 18 November 2014 worth over $3,072,500. On average, Arch trades about 250,000 units every 0 days since 2014. As of 18 November 2014 Arch still owns at least 12,301 units of Concert Pharmaceuticals Inc stock.

You can see the complete history of Arch J stock trades at the bottom of the page.



Insiders trading at Concert Pharmaceuticals Inc

Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V..., and Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.



What does Concert Pharmaceuticals Inc do?

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.



What does Concert Pharmaceuticals Inc's logo look like?

Concert Pharmaceuticals Inc logo

Complete history of Arch J stock trades at Concert Pharmaceuticals Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
18 Nov 2014 Arch Management Iv, L.L.C.J...
Sale 250,000 $12.29 $3,072,500
18 Nov 2014
12,301


Concert Pharmaceuticals Inc executives and stock owners

Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include: